A detailed history of Harding Loevner LP transactions in Bio N Tech Se stock. As of the latest transaction made, Harding Loevner LP holds 2,325 shares of BNTX stock, worth $262,911. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,325
Previous 2,926,761 99.92%
Holding current value
$262,911
Previous $235 Million 99.88%
% of portfolio
0.0%
Previous 1.34%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$78.36 - $124.66 $229 Million - $365 Million
-2,924,436 Reduced 99.92%
2,325 $276,000
Q2 2024

Aug 14, 2024

SELL
$80.36 - $102.87 $71.6 Million - $91.7 Million
-891,402 Reduced 23.35%
2,926,761 $235 Million
Q1 2024

May 15, 2024

SELL
$88.96 - $112.35 $11.2 Million - $14.2 Million
-126,311 Reduced 3.2%
3,818,163 $352 Million
Q4 2023

Feb 14, 2024

BUY
$90.91 - $112.75 $359 Million - $445 Million
3,944,474 New
3,944,474 $416 Million
Q2 2022

Aug 15, 2022

BUY
$123.25 - $186.24 $148,146 - $223,860
1,202 New
1,202 $179,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Harding Loevner LP Portfolio

Follow Harding Loevner LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

News

Stay updated on Harding Loevner LP with notifications on news.